IP Library › Granted Patent US 12,246,026
Granted Patent B2
US 12,246,026 · App. 17/393,566 · Granted Mar 11, 2025

Ganaxolone for use in treatment of status epilepticus

Inventors: David Czekai (Radnor, PA); Maciej Gasior (Radnor, PA); Lorianne Masuoka (Radnor, PA); Julia Tsai (Radnor, PA); Joseph Hulihan (Radnor, PA); Alex Aimetti (Radnor, PA)
Assignee: Marinus Pharmaceuticals, Inc.
A61K31/573A61K9/0019A61P25/08
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,246,026
App. No.
17/393,566
Granted
Mar 11, 2025
Kind
B2
Abstract

This invention relates to methods for treating status epilepticus by administering to the subject in need thereof an intravenous bolus of ganaxolone and a continuous intravenous infusion of a neurosteroid. The method provides SE suppression and continued suppression of SE.

Claims (28)

1. A method for treating status epilepticus (SE), comprising administering to a subject in need thereof:

a) an intravenous bolus of ganaxolone in an amount sufficient to suppress SE, and

b) a continuous intravenous infusion of ganaxolone in an amount sufficient for continued SE suppression, wherein the continuous intravenous infusion i) is initiated periprocedurally with the intravenous bolus, ii) is administered for a treatment period of about 24 hours to about 36 hours and the amount of ganaxolone infused is decreased at least twice during the treatment period, and iii) is intended to produce a ganaxolone plasma concentration in the subject of at least about 500 ng/ml to about 1000 ng/ml for at least about 8 hours to about 12 hours.

2. The method of claim 1 , wherein the intravenous bolus and the continuous intravenous infusion does not result in anesthesia of the subject.

3. The method of claim 1 , wherein the intravenous bolus produces a ganaxolone plasma concentration in the subject of at least about 500 ng/ml to about 1000 ng/ml.

4. The method of claim 1 , wherein the amount of ganaxolone administered to the subject per hour by continuous intravenous infusion is decreased over a period of about 24 hours from the initiation of the continuous intravenous infusion.

5. The method of claim 1 , wherein the amount of ganaxolone administered to the subject per hour by continuous intravenous infusion is first decreased about 2 hours after the initiation of the continuous intravenous infusion.

6. The method of claim 5 , wherein the amount of ganaxolone administered to the subject per hour by continuous intravenous infusion is first decreased by about 50%, relative to the amount administered per hour at the initiation of the continuous intravenous infusion, about 2 hours after the initiation of the continuous intravenous infusion.

7. The method of claim 5 , wherein the amount of ganaxolone administered to the subject per hour by continuous intravenous infusion is decreased a second time about 10 hours to about 14 hours after the initiation of the continuous intravenous infusion.

8. The method of claim 7 , wherein the amount of ganaxolone administered to the subject per hour by continuous intravenous infusion is decreased by about 75%, relative to the amount administered per hour at the initiation of the continuous intravenous infusion, about 10 hours to about 14 hours after the initiation of the continuous intravenous infusion.

9. The method of claim 1 , wherein the amount of ganaxolone administered to the subject per hour by continuous intravenous infusion is first decreased about 2 hours after the initiation of the continuous intravenous infusion, and then decreased again about 10 hours to about 14 hours after the initiation of the continuous intravenous infusion.

10. The method of claim 9 , wherein the amount of ganaxolone administered to the subject per hour by continuous intravenous infusion is decreased by about 50%, relative to the amount administered per hour at the initiation of the continuous intravenous infusion, about 2 hours after the initiation of the continuous infusion, and then by about 75%, relative to the amount administered per hour at the initiation of the continuous intravenous infusion, about 10 hours to about 14 hours after the initiation of the continuous infusion.

11. The method of claim 1 , wherein the amount of ganaxolone administered to the subject per hour by continuous intravenous infusion is increased after about 24 hours from the initiation of the continuous intravenous infusion.

12. The method of claim 11 , wherein the amount of ganaxolone administered to the subject per hour by continuous intravenous infusion is increased by up to about 45%, relative to the amount administered per hour starting after about 24 hours after initiation of the continuous intravenous infusion.

13. The method of claim 11 , wherein the amount of ganaxolone administered to the subject per hour by continuous intravenous infusion is increased for a period up to about 12 hours.

14. The method of claim 1 , further comprising c) continuing to administer the continuous intravenous infusion for a taper period following the treatment period.

15. The method of claim 1 , wherein the taper period starts at about 36 hours from the initiation of the continuous intravenous infusion.

16. The method of claim 14 , wherein the amount of ganaxolone administered to the subject per hour by continuous intravenous infusion during the taper period is reduce by about one third about every 4 hours.

17. The method of claim 1 , wherein the intravenous bolus comprises about 5 mg to about 40 mg of ganaxolone.

18. The method of claim 1 , wherein the intravenous bolus is administered to the subject for about 1 minute to about 5 minutes.

19. The method of claim 1 , wherein about 20 mg of ganaxolone per hour to about 80 mg of ganaxolone per hour are infused into the subject during the continuous infusion treatment period.

20. The method of claim 1 , wherein about 80 mg of ganaxolone per hour are infused into the subject at the initiation of the continuous intravenous infusion.

21. The method of claim 1 , wherein the amount of ganaxolone infused into the subject by the continuous intravenous infusion is decreased to about 40 mg ganaxolone per hour and then to about 20 mg ganaxolone per hour during the treatment period.

22. The method of claim 1 , wherein about 80 mg of ganaxolone per hour is administered to the subject by the continuous intravenous infusion from initiation and for at least about 2 hours thereafter.

23. The method of claim 1 , wherein about 40 mg of ganaxolone per hour is administered to the subject by continuous intravenous infusion starting about 2 hours after initiation and for about 6 hours to about 10 hours thereafter.

24. The method of claim 1 , wherein about 20 mg of ganaxolone per hour is administered to the subject by continuous intravenous infusion starting about 12 hours after initiation and for about 12 hours to about 24 hours thereafter.

25. The method of claim 1 , wherein the amount of ganaxolone infused into the subject by continuous intravenous infusion is increased up to about 45 mg of ganaxolone per hour starting about 24 hours after initiation and for up to about 12 hours thereafter.

26. The method of claim 25 , wherein the amount of ganaxolone administered to the subject by continuous intravenous infusion does not exceed 45 mg ganaxolone per hour.

Assignments (4)
CHANGE OF NAME Recorded Jun 10, 2025
From: MARINUS PHARMACEUTICALS, INC.
To: IMMEDICA PHARMA US INC.
Reel/Frame 071375/0224 →
RELEASE OF SECURITY INTEREST Recorded Feb 13, 2025
From: SAGARD HEALTHCARE PARTNERS FUNDING COMPANY SPE 1, LLC
To: MARINUS PHARMACEUTICALS, INC.
Reel/Frame 070204/0035 →
SECURITY INTEREST Recorded Oct 28, 2022
From: MARINUS PHARMACEUTICALS, INC.
To: SAGARD HEALTHCARE ROYALTY PARTNERS, LP
Reel/Frame 061580/0171 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 4, 2021
From: CZEKAI, DAVID; GASIOR, MACIEJ; MASUOKA, LORIANNE; TSAI, JULIA; HULIHAN, JOSEPH; AIMETTI, ALEX
To: MARINUS PHARMACEUTICALS, INC.
Reel/Frame 057078/0006 →
Continuity (4)
Continuation 17186569 · Feb 26, 2021
Continuation PCTUS2020044843 · Aug 4, 2020
Provisional Application 62882648 · Aug 5, 2019
Related Publication 20220202831A1 · Jun 30, 2022
References Cited (239)
US 2671750A · Macek · 1954 [cited by applicant]
US 4540602A · Motoyama et al. · 1985 [cited by applicant]
US 4783484A · Violante et al. · 1988 [cited by applicant]
US 4826689A · Violanto et al. · 1989 [cited by applicant]
US 4997454A · Violante et al. · 1991 [cited by applicant]
US 5134127A · Stella et al. · 1992 [cited by applicant]
US 5145684A · Liversidge et al. · 1992 [cited by applicant]
US 5209746A · Balahan et al. · 1993 [cited by applicant]
US 5213808A · Bar-Shalom et al. · 1993 [cited by applicant]
US 5221278A · Linkwitz et al. · 1993 [cited by applicant]
US 5260068A · Chen · 1993 [cited by applicant]
US 5260069A · Chen · 1993 [cited by applicant]
US 5298262A · Na et al. · 1994 [cited by applicant]
US 5299131A · Haas et al. · 1994 [cited by applicant]
US 5312390A · Wong · 1994 [cited by applicant]
US 5318588A · Horzewski et al. · 1994 [cited by applicant]
US 5340590A · Wong et al. · 1994 [cited by applicant]
US 5346702A · Na et al. · 1994 [cited by applicant]
US 5352459A · Hollister et al. · 1994 [cited by applicant]
US 5356476A · Oshlack et al. · 1994 [cited by applicant]
US 5376645A · Stella et al. · 1994 [cited by applicant]
US 5391381A · Wong et al. · 1995 [cited by applicant]
US 5399363A · Liversidge et al. · 1995 [cited by applicant]
US 5429824A · June · 1995 [cited by applicant]
US 5445829A · Paradissis et al. · 1995 [cited by applicant]
US 5456679A · Balaban et al. · 1995 [cited by applicant]
US 5470583A · Na et al. · 1995 [cited by applicant]
US 5472708A · Chen · 1995 [cited by applicant]
US 5494683A · Liversidge et al. · 1996 [cited by applicant]
US 5508040A · Chen · 1996 [cited by applicant]
US 5510118A · Bosch et al. · 1996 [cited by applicant]
US 5518187A · Bruno et al. · 1996 [cited by applicant]
US 5534270A · De Castro · 1996 [cited by applicant]
US 5543133A · Swanson · 1996 [cited by applicant]
US 5560932A · Bagchi et al. · 1996 [cited by applicant]
US 5573783A · Desieno et al. · 1996 [cited by applicant]
US 5629277A · Plishka · 1997 [cited by applicant]
US 5662883A · Bagchi et al. · 1997 [cited by applicant]
US 5665331A · Bagchi et al. · 1997 [cited by applicant]
US 5672360A · Sackler et al. · 1997 [cited by applicant]
US 5718388A · Czekai et al. · 1998 [cited by applicant]
US 5741522A · Violante et al. · 1998 [cited by applicant]
US 5776496A · Violante et al. · 1998 [cited by applicant]
US 5840329A · Bai · 1998 [cited by applicant]
US 5862999A · Czekai et al. · 1999 [cited by applicant]
US 5980508A · Cardanibe et al. · 1999 [cited by applicant]
US 6039979A · Gendrot et al. · 2000 [cited by applicant]
US 6161536A · Redmon et al. · 2000 [cited by applicant]
US 6214379B1 · Hermelin · 2001 [cited by applicant]
US 6228398B1 · Devane et al. · 2001 [cited by applicant]
US 6248363B1 · Patel et al. · 2001 [cited by applicant]
US 6264922B1 · Wood et al. · 2001 [cited by applicant]
US 6267989B1 · Liversidge et al. · 2001 [cited by applicant]
US 6316029B1 · Jain et al. · 2001 [cited by applicant]
US 6375986B1 · Ryde et al. · 2002 [cited by applicant]
US 6423746B1 · Yarbrough et al. · 2002 [cited by applicant]
US 6428814B1 · Bosch · 2002 [cited by applicant]
US 6432381B2 · Liversidge et al. · 2002 [cited by applicant]
US 6514518B2 · Monkhouse et al. · 2003 [cited by applicant]
US 6569463B2 · Patel et al. · 2003 [cited by applicant]
US 6592903B2 · Ryde et al. · 2003 [cited by applicant]
US 6607751B1 · Odidi et al. · 2003 [cited by applicant]
US 6627223B2 · Percel et al. · 2003 [cited by applicant]
US 6682759B2 · Lim et al. · 2004 [cited by applicant]
US 6689378B1 · Sun et al. · 2004 [cited by applicant]
US 6730325B2 · Devane et al. · 2004 [cited by applicant]
US 6793936B2 · Devane et al. · 2004 [cited by applicant]
US 6902742B2 · Devane et al. · 2005 [cited by applicant]
US 6908626B2 · Cooper et al. · 2005 [cited by applicant]
US 6923988B2 · Patel et al. · 2005 [cited by applicant]
US 6969529B2 · Bosch · 2005 [cited by applicant]
US 6976647B2 · Reed et al. · 2005 [cited by applicant]
US 7078057B2 · Kerkhof · 2006 [cited by applicant]
US 7198795B2 · Cooper et al. · 2007 [cited by applicant]
US 7550445B2 · Nerurkar et al. · 2009 [cited by applicant]
US 7842232B2 · Bosch · 2010 [cited by applicant]
US 7858609B2 · Shaw et al. · 2010 [cited by applicant]
US 8022054B2 · Shaw et al. · 2011 [cited by applicant]
US 8252228B1 · Freeman et al. · 2012 [cited by applicant]
US 8318714B2 · Shaw et al. · 2012 [cited by applicant]
US 8362286B2 · Shaw et al. · 2013 [cited by applicant]
US 8367651B2 · Shaw et al. · 2013 [cited by applicant]
US 8455002B2 · Shaw et al. · 2013 [cited by applicant]
US 8604011B2 · Mellon · 2013 [cited by applicant]
US 8618087B2 · Shaw et al. · 2013 [cited by applicant]
US 8658692B2 · Kim et al. · 2014 [cited by applicant]
US 8697678B2 · Goodchild et al. · 2014 [cited by applicant]
US 8975245B2 · Goodchild et al. · 2015 [cited by applicant]
US 9017728B2 · Shaw et al. · 2015 [cited by applicant]
US 9029355B2 · Shaw et al. · 2015 [cited by applicant]
US 9056116B2 · Shaw et al. · 2015 [cited by applicant]
US 9452176B2 · Shaw et al. · 2016 [cited by applicant]
US 11110100B2 · Czekai · 2021 [cited by examiner]
US 11395817B2 · During · 2022 [cited by applicant]
US 20020012675A1 · Jain et al. · 2002 [cited by applicant]
US 20020150616A1 · Vandercruys · 2002 [cited by applicant]
US 20030054042A1 · Liversidge et al. · 2003 [cited by applicant]
US 20030129242A1 · Bosch et al. · 2003 [cited by applicant]
US 20030215502A1 · Pruss et al. · 2003 [cited by applicant]
US 20040067251A1 · Johnston et al. · 2004 [cited by applicant]
US 20040105778A1 · Lee et al. · 2004 [cited by applicant]
US 20040105889A1 · Ryde et al. · 2004 [cited by applicant]
US 20040214746A1 · Bosch et al. · 2004 [cited by applicant]
US 20040224020A1 · Schoenhard · 2004 [cited by applicant]
US 20040258757A1 · Bosch et al. · 2004 [cited by applicant]
US 20050031691A1 · McQurk et al. · 2005 [cited by applicant]
US 20050118268A1 · Percel et al. · 2005 [cited by applicant]
US 20050181050A1 · Hirsch et al. · 2005 [cited by applicant]
US 20050196416A1 · Kipp et al. · 2005 [cited by applicant]
US 20050226927A1 · Han et al. · 2005 [cited by applicant]
US 20050232890A1 · Hoath et al. · 2005 [cited by applicant]
US 20060003005A1 · Cao et al. · 2006 [cited by applicant]
US 20060216353A1 · Liversidge et al. · 2006 [cited by applicant]
US 20070141161A1 · Shaw et al. · 2007 [cited by applicant]
US 20070148252A1 · Shaw et al. · 2007 [cited by applicant]
US 20090004262A1 · Shaw et al. · 2009 [cited by applicant]
US 20110236487A1 · Shaw et al. · 2011 [cited by applicant]
US 20110306579A1 · Stein · 2011 [cited by applicant]
US 20120052098A1 · Shaw et al. · 2012 [cited by applicant]
US 20140057885A1 · Reddy et al. · 2014 [cited by applicant]
US 20140066417A1 · Goodchild et al. · 2014 [cited by applicant]
US 20140235600A1 · Covey et al. · 2014 [cited by applicant]
US 20140249120A1 · Covey et al. · 2014 [cited by applicant]
US 20150018327A1 · Reddy · 2015 [cited by applicant]
US 20150158903A1 · Upasani et al. · 2015 [cited by applicant]
US 20150175651A1 · Salituro et al. · 2015 [cited by applicant]
US 20150291654A1 · Upasani et al. · 2015 [cited by applicant]
US 20150315230A1 · Covey et al. · 2015 [cited by applicant]
US 20150335659A1 · Jones et al. · 2015 [cited by applicant]
US 20160228454A1 · Zhang · 2016 [cited by examiner]
US 20170202855A1 · Shaw et al. · 2017 [cited by applicant]
US 20170246188A1 · Reddy · 2017 [cited by applicant]
US 20170258812A1 · Zhang et al. · 2017 [cited by applicant]
US 20180071315A1 · Cashman et al. · 2018 [cited by applicant]
CA 2541811C · 2005 [cited by applicant]
CA 2892811A1 · 2014 [cited by applicant]
CA 2960611A1 · 2016 [cited by applicant]
EP 169618A2 · 1986 [cited by applicant]
EP 498824A1 · 1992 [cited by applicant]
EP 499299A2 · 1992 [cited by applicant]
EP 580690A1 · 1994 [cited by applicant]
JP 2009524582A1 · 2009 [cited by applicant]
WO 9526715A2 · 1995 [cited by applicant]
WO 9857648A1 · 1998 [cited by applicant]
WO 145677A1 · 2001 [cited by applicant]
WO 2007062266A1 · 2007 [cited by applicant]
WO 2008066899A2 · 2008 [cited by applicant]
WO 2011088503A1 · 2011 [cited by applicant]
WO 2013063279A1 · 2013 [cited by applicant]
WO 2013112605A2 · 2013 [cited by applicant]
WO 2014028398A2 · 2014 [cited by applicant]
WO 2014085668A1 · 2014 [cited by applicant]
WO 2014127201A1 · 2014 [cited by applicant]
WO 2014160441A1 · 2014 [cited by applicant]
WO 2014160480A1 · 2014 [cited by applicant]
WO 2014169831A1 · 2014 [cited by applicant]
WO 2014169832A1 · 2014 [cited by applicant]
WO 2014169833A1 · 2014 [cited by applicant]
WO 2014169836A1 · 2014 [cited by applicant]
WO 2015010054A1 · 2015 [cited by applicant]
WO 2015081170 · 2015 [cited by applicant]
WO 2015180679A1 · 2015 [cited by applicant]
WO 2016040322A1 · 2016 [cited by applicant]
WO 2017066626A1 · 2017 [cited by applicant]
WO 2017156103A1 · 2017 [cited by applicant]
WO 2018031748A1 · 2018 [cited by applicant]
International Search Report and Written Opinion in PCT/US2020/044843, dated Nov. 18, 2020. [cited by applicant]
Horioka et al., “Injection Agent—Basics, Preparations, and Applications,” Nanzando Co. Ltd., pp. 20-25 (1995). [cited by applicant]
Loftsson, et al., “Expert Opinion on Drug Delivery”, Cyclodextrins in drugs delivery, pp. 335-351 (2005). [cited by applicant]
Fabian, “Azabenzenes (azines)—The nitrogen derivatives of benzene with one to six N atoms: Stability. homodesmotic stabilization energy, electron distribution, and magnetic ring current; a computational study” Canadian … [cited by applicant]
Press Release: “Marinus Pharmaceuticals' Ganaxolone IV Demonstrates Robust Efficacy in Benzodiazepine-Resistant Models of Status Epilepticus,” Published on Apr. 19, 2016, (available at: https://ir.marinuspharma.com/news… [cited by applicant]
Marinus Pharmaceuticals, “Marinus Pharmaceuticals, Inc. enters into use agreement with CyDex Pharmacweuticals, Inc. for use of Captisol® for Ganaxolone IV,” Aug. 12, 2014, Retrieved from the Internet: URL: http://ir.mar… [cited by applicant]
Monaghan et al., “Initial Human Experience with Ganaxolone, a Neuroactive Steroid with Antiepileptic Activity” Epilepsia, vol. 38(9), pp. 1026-1031 (1997). [cited by applicant]
Mula, “Emerging drugs for focal epilepsy.” Expert Opinion on Emerging Drugs,18(1):87-95, (2013). [cited by applicant]
Sham et al., “Formulation and characterization of spray-dried powders containing nanoparticles for aerosol delivery to the lung”, International Journal of Pharmaceuticals, vol. 269, pp. 45 (2004). [cited by applicant]
Valotis et al., “Human Receptor Kinetics, Tissue Binding Affinity, and Stability of Mometasone Furoate” Journal of Pharmaceutical Sciences, vol. 93(5). 14 Pages. [cited by applicant]
Captisol, accessed from www.captisol.com website maintained by Ligand, on Sep. 26, 2019, five pages. [cited by applicant]
Hogenkamp et al.; “Synthesis and in Vitro Activity of 3Beta-Substituted-3Alpha-hydroxypregnan-20-ones:Allocteric Modulations of the GABA(A) Receptor”; J. Med. Chem., 40; pp. 61-72 (1997). [cited by applicant]
Nohria et al.; “Ganaxolone”; The Journal of the American Society for Experimental Neuro Therapeutics; vol. 4; pp. 102-105 (2004). [cited by applicant]
Pramanick et al.; “Excipient Selection in Parenteral Formulation Development”; Pharma Times, vol. 45(3); pp. 65-77 (2013). [cited by applicant]
Rogawski et al.; “Neuroactive Steroids for the Treatment of Status Epilepticus”; Epilepsia, vol. 54(6); pp. 93-98 (2013). [cited by applicant]
Rosetti et al.; “Management of Refractory Status Epilepticus in Adults: Still More Questions Than Answers”; Lancet Nuerol., vol. 10; pp. 922-930 (2011). [cited by applicant]
Shorvon et al.; “The Treatment of Super-Refractory Status Epilepticus: A Critical Review of Available Therapies and a Clinical Treatment Protocol”, Brain, vol. 134; pp. 2802-2818 (2011). [cited by applicant]
Botella, et al., “Neuroactive Steroids. 1. Positive Allosteric Modulators of the (gamma-Aminobutyric Acid)a eceptor: Structure-Activity Relationships of Heterocyclic Substitution at C-21” Journal of Medicinal Chemistry,… [cited by applicant]
Wong et al. “Suspensions for intravenous (IV) injection: A review of development, preclinical and clinical aspects,” Advanced Drug Delivery Reviews, vol. 60, pp. 939-954 (2008). [cited by applicant]
Moyne, et al., “Sterilization of injectable drugs solutions by irradiation” Radiation Physics and Chemistry, vol. 63; pp. 703-704 (2002). [cited by applicant]
Chai, et al., “Protective effect of polysaccharides on the stability of parenteral emulsions,” Drug Development and Industrial Pharmacy, 2013; vol. 39(5), pp. 646-656. [cited by applicant]
Press Release: “Marinus Pharmaceuticals Provides Business Update and Reports Second Quarter 2016 Financial Results,” Published on Aug. 9, 2016 (available at: https://ir.marinuspharma.com/news/news-details/2016/Marinus-P… [cited by applicant]
Marques, “Dissolution Technologies”, Simulated Biological Fluids with Possible Application in Dissolution Testing, p. 15-28.(2011). [cited by applicant]
“VFEND Full Prescibing Information,” updated Jan. 2019, 37 pages. [cited by applicant]
Saporito et al., Intravenous Administration of Ganaxolone Attenuates Electroencephalographic Seizures in a Diazepam Resistant Model of Status Epilepticus, Neurobiology, 86 (16 supplement), published Apr. 4, 2016. [cited by applicant]
Press Release: “Marinus Pharmaceuticals Doses First Subject in Phase 1 Clinical Trial for Ganaxolone IV,” Published on Jun. 22, 2016, Available at: https://ir.marinuspharma.com/news/news-details/2016/Marinus-Pharmaceuti… [cited by applicant]
Press Release: “Marinus Pharmaceuticals Receives FDA Orphan Drug Designation for Ganaxolone IV to Treat Status Epilepticus,” Published Apr. 15, 2016, Available at: https://ir.marinuspharma.com/news/news-details/2016/Mar… [cited by applicant]
Chez, “Ganaxolone Therapy Improves Interictal EEG and Seizure Control in Lennox Gastaut Syndrome in Patients with PCDH19 and CDKL5,” Annals of Neurol. 80 (suppl 20)published Oct. 26, 2016. [cited by applicant]
Liptakova, et al., “Effect of Ganaxolone on Flurothyl Seizures in Developing Rats,” Epilepsia, 41(7):788-793 (2000). [cited by applicant]
Pieribone, et al., “Clinical Evaluation of Ganaxolone in Pediatric and Adolescent Patients with Refractory Epilepsy” Epilepsia, vol. 48(10), 5 pages (2007). [cited by applicant]
Saporito, et al., Ganaxolone Administered Intravenously Prevents Behavioral Seizures and Promotes Survival in the Rat Lithium-Pilocarpine Model of Status Epilepticus, Neurology, 86 (16 Supplement), published Apr. 5, 201… [cited by applicant]
Press Release: “Marinus Announces Clinical Development Plans for Ganaxolone Intravenous Formulation,” Published on Oct. 29, 2015 (available at: https://ir.marinuspharma.com/news/news-details/2015/Marinus-Announces-Clini… [cited by applicant]
Reddy and Kuruba, “Experimental Models of Status Epilepticus and Neuronal Injury for Evaluation of Therapeutic Interventions,” Int. J. Mol. Sci. 14:18284-318 (2013). [cited by applicant]
Seinfeld et al., “Status Epilepticus,” in Additional Perspectives on Epilepsy: The Biology of a Spectrum Disorder (Cold Spring Harbor Laboratory Press, 2016, ed. Gregory L. Holmes and Jeffrey L Noebels). [cited by applicant]
Imtiyaz et al., “The Evolution of the Pilocarpine Animal Model of Status Epilepticus,” Heliyon (2020) e04557(2020). [cited by applicant]
Turski, et al. “Review: Cholinergic Mechanisms and Epileptogenesis. The Seizures Induced by Pilocarpine: A Novel Experimental Model of Intractable Epilepsy,” Synapse 3: 154-171 (1989). [cited by applicant]
Kokate et al., “Neuroactive Steroids Protect Against Pilocarpine- and Kainic Acid-induced Limbic Seizures and Status Epilepticus in Mice,” Neuropharmacology, 35(8): 1049-1056 (1996). [cited by applicant]
American Academy of Neurology (“AAN”) 2016 Annual Meeting Scientific Abstract Listing and Meeting Information AAN 2016 Annual Meeting, Vancouver, BC, Canada, Apr. 15, 2016, Available at: https://issuu.com/americanacadem… [cited by applicant]
Saporito et al., “Ganaxolone Administered Intravenously Prevents Behavioral Seizures and Promotes Survival in the Rat Lithium-Pilocarpine Model of Status Epilepticus,” Poster, presented Apr. 17, 2016, at the 2016 AAN An… [cited by applicant]
Saporito et al., “Intravenous Administration of Ganaxolone Attenuates Electroencephalographic Seizures in a Diazepam Resistant Model of Status Epilepticus,” Poster, presented Apr. 19 and Apr. 20, 2016, at the 2016 AAN A… [cited by applicant]
Saporito et al., “Ganaxolone Administered IV Blocks Experimental Status Epilepticus,” “Data Blitz” Presentation, Apr. 20, 2016, at the 2016 AAN Annual Meeting. [cited by applicant]
Wylie et al., Status Epilepticus. [Updated May 15, 2022]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; Jan. 2022—. Available from: https://www.ncbi.nlm.nih.gov/books/NBK430686/. [cited by applicant]
Trinka et al., “A definition and classification of status epilepticus—Report of the ILAE Task Force on Classification of Status Epilepticus.” Epilepsia, 56(10):1515-1523 (2015). [cited by applicant]
Tsai et al., “Phase I Study to Determine the Pharmaceutics, Pharmacodynamics, and Safety of IV Ganaxolone in Healthy Adults,” Abstract of Poster Presented at the 6th London-Innsbruck Colloquium on Status Epilepticus and… [cited by applicant]
Drug Development and Review Definitions, Aug. 20, 2015, Available at: https://www.fda.gov/drugs/investigational-new-drug-ind-application/drug-development-and-review-definitions. [cited by applicant]
Press Release: “Marinus Pharmaceuticals Doses First Subject in Phase I Clinical Trial for Ganaxolone IV,” Published on Jun. 22, 2016, Available at: https://ir.marinuspharma.com/news/news-details/2016/Marinus-Pharmaceuti… [cited by applicant]
Carter et al., “Characterization of the Anticonvulsant Properties of Ganaxolone (CCD 1042: 3α-Hydroxy-3β-methyl-5α-pregnan-20-one), a Selective, High-Affinity, Steroid Modulator of the γ-Aminobutyric AcidA Receptor,” Th… [cited by applicant]
Saporito et al., Intravenous Administration of Ganaxolone Attenuates Electroencephalographic Seizures in a Diazepam Resistant Model of Status Epilepticus, Neurobiology, 86 (16 supplement), Abstract, published Apr. 4, 20… [cited by applicant]
Saporito et al., Ganaxolone Administered Intravenously Prevents Behavioral Seizures and Promotes Survival in the Rat Lithium-Pilocarpine Model of Status Epilepticus, Neurology 86 (16 Supplement), Abstract, published Apr… [cited by applicant]
Chez, “Ganaxolone Therapy Improves Interictal EEG and Seizure Control in Lennox Gastaut Syndrome in Patients with PCDH19 and CDKL5,” Annals of Neurol. 80 (suppl 20), S326 published Oct. 26, 2016. [cited by applicant]
Petition for an Inter Partes Review of U.S. Pat. No. 11,110,100, United States Patent & Trademark Office, Before the Patent Trial and Appeal Board, Case IPR2024-00726, U.S. Pat. No. 11,110,100 B2, dated Mar. 26, 2024. [cited by applicant]
NCT03350035 Clinical Trial Study Details, ClinicalTrials.gov (Nov. 17, 2017), https://clinicaltrials.gov/study/NCT03350035?term= NCT03350035&rank=1&tab=history&a=1 (last visited Sep. 28, 2023). [cited by applicant]
Tsai et al., “Phase I study to determine the pharmacokinetics, pharmacodynamics, and safety of IV ganaxolone in healthy adults, Final Programme of the 6th London-Innsbruck Colloquium on Status Epilepticus and Acute Seiz… [cited by applicant]
Tsai et al., Phase I Study to Determine the Pharmacokinetics, Pharmacodynamics, and Safety of IV Ganaxolone in Healthy Adults 80 Annals of Neurology S77-78 (Supp. 20 2016). [cited by applicant]
Ganaxolone Phase 1 Data Supports Progressing to Phase 2 in Patientswith Status Epilepticus, Clinical Leader (Oct. 19, 2016), https://www.clinicalleader.com/doc/ganaxolone-phase-data-progressing-phase-patients-epilepticu… [cited by applicant]
Ramsay et al., “Pharmacokinetic and Pharmacodynamic (PK/PD) Relationship of Intravenous Ganaxolone in Refractory Status Epilepticus,” (Nov. 25, 2019), https://aesnet.org/abstractslisting/pharmacokinetic-and-pharmacodyna… [cited by applicant]
Husain et al., “Intravenous Ganaxolone Achieves Rapid and Dose-Dependent Sustained Improvement in EEG Seizure Burden in Patients with Refractory Status Epilepticus,” 37 J. Clin. Neurophysiol. 332 (Jul. 2020). [cited by applicant]
Treatment of Refractory Status Epilepticus Prevents Need for Induced Coma with Intravenous Anesthetics in Phase 2 Trial, Practical Neurology (Oct. 18, 2019), https://practicalneurology.com/news/treatment-of-refractory-s… [cited by applicant]
Ramsay, “Pharmacokinetic and Pharmacodynamic (PK/PD) Relationship of Intravenous Ganaxolone in Refractory Status Epilepticus, Marinus Pharmaceuticals,” (Dec. 7, 2019), https://marinuspharma.com/wp-content/uploads/2020/0… [cited by applicant]
Reddy et al., “Experimental Models of Status Epilepticus and Neuronal Injury for Evaluation of Therapeutic Interventions,” 14 Int'l J. Mol. Sci. 18284-318 (2013). [cited by applicant]
Marinus Corporate Presentation Jun. 2023, Marinus Pharmaceuticals (Jun. 2023), https://s25.q4cdn.com/443656056/files/doc_financials/ 2023/Corporate-Deck-June-FINAL.pdf (last visited Jun. 19, 2023). [cited by applicant]
Vaitkevicius, “Intravenous ganaxolone for the treatment of refractory status epilepticus: Results from an open-label, dose-finding, phase 2 trial, 63 Epilepsia,” 2381-91 (2022). [cited by applicant]
Hixson, “Stopping Antiepileptic Drugs: When and Why?, 12 Current Treatment Options in Neurology,” 434-442 (2010). [cited by applicant]
Ozdemir et al., “Efficacy of continuous midazolam infusion and mortality in childhood refractory generalized convulsive status epilepticus,” 14 Seizure 129-132 (2005). [cited by applicant]
Sperling et al., “Randomized, double-blind, placebo-controlled phase 2 study of ganaxolone as add-on therapy in adults with uncontrolled partial-onset seizures,” 58 Epilepsia 558-564 (2017). [cited by applicant]
Tsai et al., “Phase 1 Study to Determine the Pharmacokinetics, Pharmacodynamics, and Safety of IV Ganaxolone in Healthy Adults,”. [cited by applicant]
Broomall et al., “Pediatric Super-Refractory Status Epilepticus Treated with Allopregnanolone,” 76 Ann Neurol. 911-915 (2014). [cited by applicant]
Zolkowska et al., “Intramuscular allopregnanolone and ganaxolone in a mouse model of treatment-resistant status epilepticus,” 59 Epilepsia 220-227 (Supp. 2 2018). [cited by applicant]
Vaitkevicius et al., “First-in-man allopregnanolone use in super-refractory status epilepticus,” 4 Annals of Clinical Translational Neurol. 411-414 (2017). [cited by applicant]
Sankar, “Treatment of status epilepticus: Physiology, pharmacology, and future directions,” Epilepsia Open 1-8 (May 2023), https://onlinelibrary.wiley.com/doi/epdf/10.1002/epi4.12725. [cited by applicant]
Marinus Pharmaceuticals Presents Clinical Data of Ganaxolone in Pediatric Epilepsies at Antiepileptic Drug and Device Trials XIII Conference, Marinus Pharmaceuticals (May 18, 2015), https://ir.marinuspharma.com/news/new… [cited by applicant]
Currie, “Pharmacology, Part 2: Introduction to Pharmacokinetics,” 46 J. Nuclear Med. Tech. 221-30 (Sep. 2018). [cited by applicant]
141st Annual Meeting of the American Neurological Society, Annals of Neurology, S1-S265, https://onlinelibrary.wiley.com/doi/10.1002/ana.24759 (last accessed Feb. 8, 2024). [cited by applicant]